Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation

被引:162
作者
Gloor, J. M. [1 ]
Cosio, F. G.
Rea, D. J.
Wadei, H. M.
Winters, J. L.
Moore, S. B.
DeGoey, S. R.
Lager, D. J.
Grande, J. P.
Stegall, M. D.
机构
[1] Mayo Clin & Mayo Fdn, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN USA
[2] Mayo Clin & Mayo Fdn, Dept Surg, Div Transplant Surg, Rochester, MN USA
[3] Mayo Clin & Mayo Fdn, Dept Pathol, Div Lab Med, Rochester, MN USA
[4] Mayo Clin & Mayo Fdn, Dept Pathol, Div Anat Pathol, Rochester, MN USA
关键词
ABO incompatible; kidney transplantation; positive crossmatch;
D O I
10.1111/j.1600-6143.2006.01416.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Recent protocols have allowed successful positive crossmatch (+XM) and ABO incompatible (ABOI) kidney transplantation, although their long-term outcome is not clear. To begin to assess this issue we compared protocol biopsies performed 12 months posttransplant in 37 +XM, 24 ABOI and 198 conventional allografts. Although the majority in all three groups had only minimal histologic changes, transplant glomerulopathy (TG) was significantly increased in +XM (22% vs. 13% ABOI vs. 8% conventional, p = 0.015), and correlated with prior humoral rejection (HR) by multivariate analysis (odds ratio 17.5, p <= 0.0001). Patients with a prior history of HR also had a significant increase in interstitial fibrosis (No HR 54% vs. HR 86%, p = 0.045). In the absence of HR no difference in histologic changes was seen between groups, although all three groups had a demonstrable mild increase in interstitial fibrosis from biopsies performed at the time of transplant. Thus, although HR is associated with an increase in TG, in its absence allograft histology is similar in +XM, ABOI and conventional allografts 1 year posttransplant.
引用
收藏
页码:1841 / 1847
页数:7
相关论文
共 33 条
[1]   Intravenous immunoglobulin and Thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients [J].
Akalin, E ;
Ames, S ;
Sehgal, V ;
Fotino, M ;
Daly, L ;
Murphy, B ;
Bromberg, JS .
TRANSPLANTATION, 2003, 76 (10) :1444-1447
[2]   Accommodation of vascularized xenografts: Expression of ''protective genes'' by donor endothelial cells in a host Th2 cytokine environment [J].
Bach, FH ;
Ferran, C ;
Hechenleitner, P ;
Mark, W ;
Koyamada, N ;
Miyatake, T ;
Winkler, H ;
Badrichani, A ;
Candinas, D ;
Hancock, WW .
NATURE MEDICINE, 1997, 3 (02) :196-204
[3]   Predicting subsequent decline in kidney allograft function from early surveillance biopsies [J].
Cosio, FG ;
Grande, JP ;
Wadei, H ;
Larson, TS ;
Griffin, MD ;
Stegall, MD .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (10) :2464-2472
[4]  
COSIO FG, 2005, AM J TRANSPLANT, V5, P1
[5]   Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation [J].
Fidler, ME ;
Gloor, JM ;
Lager, DJ ;
Larson, TS ;
Griffin, MD ;
Textor, SC ;
Schwab, TR ;
Prieto, M ;
Nyberg, SL ;
Ishitani, MB ;
Grande, JP ;
Kay, PA ;
Stegall, MD .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (01) :101-107
[6]   A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation [J].
Gloor, JM ;
Lager, DJ ;
Fidler, ME ;
Grande, JP ;
Moore, SB ;
Winters, JL ;
Kremers, WK ;
Stegall, MD .
TRANSPLANTATION, 2005, 80 (11) :1572-1577
[7]   Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation [J].
Gloor, JM ;
DeGoey, S ;
Ploeger, N ;
Gebel, H ;
Bray, R ;
Moore, SB ;
Dean, PG ;
Stegall, MD .
TRANSPLANTATION, 2004, 78 (02) :221-227
[8]   Overcoming a positive crossmatch in living-donor kidney transplantation [J].
Gloor, JM ;
DeGoey, SR ;
Pineda, AA ;
Moore, SB ;
Prieto, M ;
Nyberg, SL ;
Larson, TS ;
Griffin, MD ;
Textor, SC ;
Velosa, JA ;
Schwab, TR ;
Fix, LA ;
Stegall, MD .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (08) :1017-1023
[9]   ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. [J].
Gloor, JM ;
Lager, DJ ;
Moore, SB ;
Pineda, AA ;
Fidler, ME ;
Larson, TS ;
Grande, JP ;
Schwab, TR ;
Griffin, MD ;
Prieto, M ;
Nyberg, SL ;
Velosa, JA ;
Textor, SC ;
Platt, JL ;
Stegall, MD .
TRANSPLANTATION, 2003, 75 (07) :971-977
[10]   Desensitization and subsequent transplantation kidney transplantation of patient using intravenous immunoglobulins (IVIg) [J].
Glotz, D ;
Antoine, C ;
Julia, P ;
Suberbielle-Boissel, C ;
Boudjeltia, S ;
Fraoui, R ;
Hacen, C ;
Duboust, A ;
Bariety, J .
AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (08) :758-760